BridgeMD
Compares treatment options for Gastroesophageal Reflux Disease (GERD)
Official title Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease
ClinicalTrials.gov ID: NCT06564246
What this study is testing
What is Vonoprazan 20 mg versus Pantoprazole 40 mg?
Vonoprazan 20 mg versus Pantoprazole 40 mg is an investigational medicine, being studied as a potential treatment for gastroesophageal reflux disease (gerd).
Also referred to as Vononoprazan (Vonesca) versus pantoprazole (pantoloc).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 17 to 60
You may be able to join if
- Age 17-60 years.
- Both genders.
- Patients with a score ≥ 8 on the Gastroesophageal Reflux Disease Questionnaire (Gerd Q) are defined as having GERD and will enroll in this study and...
You likely can't join if
- people with history of gastrointestinal disease, gastroduodenal surgery, inflammatory bowel disease and Barrett's esophagus.
- people with an earlier or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders (gastric or duodenal ulcer).
- people with history of total/subtotal gastrectomy and esophageal achalasia.
- people with Corona virus disease (COVID19).
- people with major cardiological, respiratory, endocrine metabolic disease and neuro-psychological disease.
- Pregnancy or lactation.
See the full eligibility criteria
- Age 17-60 years.
- Both genders.
- Patients with a score ≥ 8 on the Gastroesophageal Reflux Disease Questionnaire (Gerd Q) are defined as having GERD and will enroll in this study and it will be done at baseline and after 8 weeks.
- people with history of gastrointestinal disease, gastroduodenal surgery, inflammatory bowel disease and Barrett's esophagus.
- people with an earlier or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders (gastric or duodenal ulcer).
- people with history of total/subtotal gastrectomy and esophageal achalasia.
- people with Corona virus disease (COVID19).
- people with major cardiological, respiratory, endocrine metabolic disease and neuro-psychological disease.
- Pregnancy or lactation.
- people with total bilirubin level ≥ 1.2 mg/dl and ALT level \> 100 IU/l.
- people with renal impairment (Crcl less than 30 ml/min).
- Patients receiving atazanavir sulphate, nelfinavir and rilpivirine hydrochloride due to potential drug interactions.
The study team makes the final eligibility decision.
Where it's taking place
- Giza, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 17 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.